Repare Therapeutics (NASDAQ:RPTX) Upgraded at Bloom Burton

Repare Therapeutics (NASDAQ:RPTX) was upgraded by research analysts at Bloom Burton from an “accumulate” rating to a “buy” rating in a research report issued to clients and investors on Friday, Zacks.com reports.

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Repare Therapeutics in a research report on Wednesday, February 21st.

Repare Therapeutics Stock Performance

Shares of RPTX opened at $3.15 on Friday. The company has a 50-day simple moving average of $5.30 and a 200-day simple moving average of $5.69. The firm has a market capitalization of $116.55 million, a P/E ratio of -1.41 and a beta of 0.56. Repare Therapeutics has a 52 week low of $2.98 and a 52 week high of $13.85.

Repare Therapeutics (NASDAQ:RPTX) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.11). Repare Therapeutics had a negative return on equity of 39.82% and a negative net margin of 183.43%. The business had revenue of $13.05 million during the quarter, compared to analyst estimates of $15.92 million. As a group, equities analysts forecast that Repare Therapeutics will post -2.74 earnings per share for the current year.

Institutional Trading of Repare Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Repare Therapeutics by 0.8% during the third quarter. Vanguard Group Inc. now owns 73,842 shares of the company’s stock worth $895,000 after buying an additional 600 shares during the last quarter. State Street Corp grew its stake in Repare Therapeutics by 1.2% during the third quarter. State Street Corp now owns 53,475 shares of the company’s stock worth $649,000 after buying an additional 648 shares during the last quarter. Nuveen Asset Management LLC grew its stake in Repare Therapeutics by 3.1% during the third quarter. Nuveen Asset Management LLC now owns 21,818 shares of the company’s stock worth $265,000 after buying an additional 660 shares during the last quarter. UBS Group AG grew its stake in Repare Therapeutics by 26.3% during the third quarter. UBS Group AG now owns 3,551 shares of the company’s stock worth $43,000 after buying an additional 739 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Repare Therapeutics by 5.3% during the first quarter. JPMorgan Chase & Co. now owns 25,039 shares of the company’s stock worth $356,000 after buying an additional 1,253 shares during the last quarter. 85.09% of the stock is owned by institutional investors.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.